United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Takes Position in Merck & Co., Inc. $MRK

Key Points

• United Super Pty Ltd opened a new position in Merck during the fourth quarter, buying 658,905 shares valued at about $69.4 million. The stake makes MRK its 22nd largest holding and about 1.0% of its portfolio.
• Merck recently delivered a mixed but generally solid quarter, with earnings and revenue both beating analyst estimates and revenue rising 4.9% year over year. The company also reaffirmed FY 2026 EPS guidance at 5.04–5.16.
• Several near-term catalysts could keep investor attention on the stock, including shareholder approval of board nominees and pay, Merck’s upcoming Jefferies Global Healthcare Conference appearance, and approval of its chicken bronchitis vaccine in China.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund acquired a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 658,905 shares of the company's stock, valued at approximately $69,356,000. Merck & Co., Inc. accounts for 1.0% of United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund's investment portfolio, making the stock its 22nd largest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in MRK. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $25,000. United Financial Planning Group LLC purchased a new stake in shares of Merck & Co., Inc. in the third quarter valued at $31,000. High Note Wealth LLC grew its position in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after purchasing an additional 109 shares during the period. Tucker Asset Management LLC purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $34,000. Finally, Wealth Watch Advisors INC purchased a new stake in shares of Merck & Co., Inc. in the third quarter valued at $34,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck shareholders approved the company’s board nominees, executive pay package, and auditor ratification at its annual meeting, reinforcing governance continuity and removing a potential overhang. Merck Shareholders Back Board, Pay and Auditor Ratification
• Positive Sentiment: Merck announced participation in the Jefferies Global Healthcare Conference, which can spark investor attention if management provides updates on pipeline progress, guidance, or strategic priorities. Merck to Participate in the Jefferies Global Healthcare Conference
• Positive Sentiment: Merck’s chicken bronchitis vaccine was approved for use in China, expanding a potential animal-health opportunity in a large market and adding a modest growth catalyst. Merck chicken bronchitis vaccine approved for use in China
• Neutral Sentiment: Merck congratulated Ontario on expanding pharmacy scope rules, a policy development that is favorable for healthcare access but has no immediate direct financial impact on MRK. Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care
• Neutral Sentiment: Merck remained a heavily watched stock in Zacks coverage and on analyst/market screens, but those mentions were not tied to a new fundamental development. Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
• Neutral Sentiment: The company’s upcoming Jefferies appearance and shareholder-call materials may keep attention on the stock, but they do not yet signal a clear change in earnings outlook. Merck & Co., Inc. (MRK) Shareholder/Analyst Call - Slideshow

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Barclays assumed coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They set an "overweight" rating and a $140.00 price target for the company. JPMorgan Chase & Co. boosted their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research report on Monday, April 6th. Royal Bank Of Canada reissued an "outperform" rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Citigroup assumed coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a "neutral" rating and a $125.00 price target for the company. Finally, Cantor Fitzgerald boosted their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a "neutral" rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $128.18.

Merck & Co., Inc. Trading Down 0.3%

NYSE:MRK opened at $119.87 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The business's 50 day moving average is $116.31 and its two-hundred day moving average is $111.41. Merck & Co., Inc. has a 52 week low of $75.40 and a 52 week high of $125.14. The company has a market cap of $296.05 billion, a PE ratio of 33.77, a P/E/G ratio of 2.71 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter last year, the business posted $2.22 EPS. Merck & Co., Inc.'s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts predict that Merck & Co., Inc. will post 5.16 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.'s dividend payout ratio is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.